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INTRODUCTION
Hodgkin’s disease (HD) is a neoplasm that 
has the characteristic of containing a small 
number of scattered large multinucleated 
or mononucleated cells, designated Reed-
Sternberg cells and Hodgkin cells respectively, 
residing in a heterogeneous admixture of in-
ﬂ ammatory and accessory cells.1,2 The paucity 
of Hodgkin and Reed-Sternberg (HRS) tumor 
cells initially made it difﬁ cult to determine the 
origins of these cells.1-3 However, high-density 
genomic expression and immunoglobulin H 
(IgH) variable-region gene rearrangements 
using single-cell analysis obtained by microdis-
section techniques have now demonstrated an 
origin in germinative B cell centers.4-9
There are few previous studies in the lit-
erature evaluating cell proliferation and this 
may be explained by the complex nature of 
this neoplasm and its heterogeneous cell com-
position.10 It has already been described that,
in HD, HRS cells express proliferating cell 
nuclear antigen (PCNA) and p53 in more than 
50% of the cases and that these expressions may 
play a role in the pathogenesis of the disease.11
PCNA is a cell cycle-associated protein that 
interferes with cell proliferation in normal and 
tumor cells. It is an essential protein in DNA 
repair. PCNA is detected by positive reaction 
for the monoclonal antibody PC-10.10,11 PCNA 
activity in DNA repair increases resistance to 
chemotherapy in which the cytotoxicity de-
pends on its integrity.12 PCNA expression in 
relapsed HD is greater than at diagnosis.12
Wild-type p53 protein encoded by the p53
gene acts in the cell cycle to interrupt it at the G1 
phase.13 This suppressive activity allows DNA 
repair in injured cells and avoids apoptosis.14
Deletion or mutation of p53 is classically associ-
ated with p53 tumor activity.13-15 Mutated p53 
has a mean half-life of six to eight hours and 
no suppressive action, and it is easily detectable 
by immunohistochemistry methods. Mutated 
p53 replaces the wild-type p53 that is present 
CONTEXT AND OBJECTIVE: Tumor cells in 
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markers that are evaluated according to the onco-
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analysis on proliferating cell nuclear antigen 
(PCNA), p53 and MDM2 (murine double minute-2) 
expression using immunohistochemistry, on formalin-
ﬁ xed, parafﬁ n-embedded tissues from diagnostic 
biopsies on 51 patients with HD. The study was 
conducted at the Division of Hematology and Trans-
fusion Medicine, Hospital São Paulo, Universidade 
Federal de São Paulo.
METHODS: Antigen expression was evaluated as 
the proportions of positive Hodgkin and Reed-
Sternberg (HRS) cells and reactive lymphocytes (L), 
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marker expression and clinical and laboratory pa-
rameters, marrow involvement, complete remission 
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KEY WORDS: Proliferating cell nuclear antigen. 
p53 genes. Proto-oncogene proteins c-mdm2. 
Hodgkin disease. Immunohistochemistry. 
in low intracellular concentrations, and has a 
shorter half-life of 20 min.13-16 p53 mutation 
is missense and occurs mainly between exons 
5 and 9.15,16 p53 mutations lead to loss of sup-
pressive function, thereby accelerating tumor 
genesis.13,14 p53 overexpression has been widely 
detected in HD, even in the absence of known 
p53 mutations.12,15,17-20 The MDM2 (murine cell 
double minute-2) gene encodes the p90 protein, 
which binds to wild-type p5317,18 to inhibit its 
suppressive activity in transcription.19,20 Associ-
ated expression of p53 and MDM2 is present in 
more than 90% of HD cases.17-19,21
The Epstein-Barr virus (EBV) genome is 
found in up to 50% of cases of HD.22 EBNA-1 
(Epstein-Barr nuclear antigen-1) bonds with p53 
and it has been suggested that EBNA-1 expres-
sion results from that interaction.23 The exact role 
of EBV in HD genesis is not clear yet.22,23
OBJECTIVE
The present study had the aims of evalua-
ting p53, PCNA and MDM2 protein expres-
sion using immunohistochemical methods, on 
formalin-ﬁ xed, parafﬁ n-embedded preserved 
tissue samples used for HD diagnosis, and 
correlating these expressions with clinical
and laboratory parameters in order to evaluate 
their impact on HD outcome.
PATIENTS AND METHODS
Patients 
Our sample consisted of 126 patients with 
HD that were followed up over the period from 
Janaury 1992 to December 1996 at Hemato-
logy Division of Unifesp/EPM. The admissions 
for the ﬁ rst-line treatment of these patients were 
from December 1976 to December 1996. Suf-
ﬁ cient parafﬁ n-embedded blocks of diagnostic 
tissues were available in relation to 51 patients 
from this sample for performing new histo-
logical analyses with hematoxylin-eosin staining 
and for making immunohistochemistry slides 
de Oliveira
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for PCNA, p53 and MDM2 analysis. Fifty-one 
other patients out of the remaining 75 were 
randomly selected as a control group. The 
parafﬁ n-embedded blocks were obtained from 
the Pathology Department of Unifesp. 
The patients’ records were retrospectively 
reviewed to collect data on gender, age, Ann 
Arbor clinical stage, B symptoms (fever, weight 
loss and night sweating), histological subtype, 
hemoglobin level, white blood count (WBC), 
erythrocyte sedimentation rate (ESR), alkaline 
phosphates and bone marrow involvement. 
First complete remission (CR) and overall 
survival (OS) were also evaluated (Table 1). 
Nine of these patients (six in the study group 
and three in the control group) were not 
evaluated with regard to the achievement of 
ﬁ rst CR and OS, but they had diagnostic and 
staging data available and therefore they were 
included because of these criteria.
The ﬁ rst patient was treated and followed up 
starting in 1976 and the remainder from 1980 
onwards. Subsequently, the treatment proto-
cols changed over the course of time. Patients 
treated before 1985 received chemotherapy us-
ing the MOPP (mechlorethamine, vincristine, 
prednisone and procarbazine) protocol, while 
those treated after that year received either 
the MOPP/ABV (MOPP plus doxorubicin, 
bleomycin and vincristine) hybrid protocol or 
the MOPP/ABVD (ABV plus dacarbazine) 
alternative regimen.24 Involved-ﬁ eld radiation 
therapy was performed on all stage I and II pa-
tients and on most stage III patients, except those 
with bulky disease, who received extended-ﬁ eld 
radiation therapy.24
There were no signiﬁ cant differences between 
the control and study groups with regard to the 
following variables: age (p = 0.19), hemoglobin 
level (p = 0.99), WBC (p = 0.53), ESR (p = 0.37) 
A and B symptoms (p = 0.14), bone marrow 
inﬁ ltration (p = 0.46), likelihood of achieving the 
ﬁ rst complete remission (CR) (p = 0.68), overall 
survival (OS) (p = 0.83) and stages (I + II, III + IV) 
(p = 0.99). In relation to histological subtypes (LP 
+ NE), (MC + LD) (LP = lymphocyte predomi-
nance; NE = nodular sclerosis; MC = mixed cel-
lularity; LD = lymphocyte depletion) (p = 0.03), 
greater frequency of NE in the study group than 
in the control group was observed.
Forty-ﬁ ve out of 51 patients in the study 
group and 48 out of 51 in the control group 
could be evaluated regarding achievement of 
ﬁ rst CR and OS. There were 12 deaths: 7/48 
(14%) and 5/45 (11%) in the control and 
studied groups, respectively. 
This study was approved by the Ethics 
Committee of Universidade Federal de São 
Paulo, and informed consent was obtained 
from all subjects who were still alive.
Methods
All the lymph node biopsies were pre-
served in formalin and embedded in paraf-
ﬁ n. Samples were then restained using the 
hematoxylin-eosin method and reviewed 
by two hematopathologists. The minimum 
immunohistochemistry panel consisted of 
anti-CD30 and CD15 antibodies. Once 
HD had been conﬁ rmed, PCNA, p53 and 
MDM2 antibodies were also included. The 
tissue sections underwent routine treatment. 
Antigenic recovery was performed by im-
mersing the slides in 0.001 M citrate buffer 
(pH 6.0) and heating in a microwave oven at 
maximum power for 45 minutes. After cool-
ing for 20 minutes at room temperature, the 
slides were washed under running water for 
ﬁ ve minutes and distilled water for a further 
ﬁ ve minutes. Endogenous peroxidase was 
then blocked by immersing the slides in 
a 0.006% hydrogen peroxide solution for 
two nine-minute periods, each followed by 
rinsing using distilled water and phosphate 
buffer solution (PBS).
Monoclonal antibodies were added at the 
concentrations recommended by the manufac-
turer, as follows. For PCNA: PC-10 (Dako, 
catalog no. MO-879) at 1/200 concentration 
for 18 hours at 4° C, followed by PBS wash-
ing; for MDM2: MDM2 (Novocastra, catalog 
no. NCR-MDM2) at 1/200 concentration; 
and for p53: DO7 (Novocastra, catalog no. 
NCL-p53DO7) and BP (Novocastra, catalog 
no. NCL-p53BP), at 1/50 concentration for 
both, incubated for 18 hours at 4º C. The 
secondary antibody was biotinylated rabbit 
anti-mouse (Dako, catalog no. E-0354), at 
1/100 concentration. Development occurred 
after incubation with the streptavidin-biotin-
peroxidase-ABC complex (Dako, catalog no. 
K-377 A-B), at 1/200 concentration for 30 
minutes at 37° C, followed by development on 
a chromogenic substrate of 3,3’ diaminoben-
zidine (PAB-Sigma, catalog no. D-5637) at 
0.006% concentration in PBS, adding 100 µl 
of hydrogen peroxide at 30 volumes for each 
10 ml of solution.25
The PCNA samples were counterstained 
with Fast-Green (Inlab, catalog no. 3870) and 
p53 and MDM2 with Harris hematoxylin. 
Negative controls were obtained from dis-
tinctive parts of the same slide, by omission 
of the tested monoclonal antibody. Positive 
controls were obtained from breast cancer 
slides that were known to be positive for p53, 
MDM2 and PCNA, which were provided by 
the pathology department of our institution. 
The number of positive cells was determined 
from the HRS and L counts. Positive cells 
were deﬁ ned as all cells with any pattern of 
nuclear staining; negative cells were those 
without this. Two of the present authors 
performed the counting, using an optical 
microscope at a magniﬁ cation of 1000 times, 
Table 1. Dichotomization and coding of variables evaluated
Code
Variable 0 1
Gender Male Female
Age < 40 years ≥ 40 years
Histological subtype LP and NE MC and LD
Clinical stage Ι and ΙΙ ΙΙΙ and ΙV
B Symptoms No Yes
Hemoglobin Level < 12 g ≥ 12 g
WBC < 10X109/l ≥ 10 X109/l
ESR < 20 mm ≥ 20 mm
Alkaline phosphatase < 150 U ≥ 150 U
Bone marrow involve-
ment* Negative Positive
%HRS + MDM2 < median (= 59.37%) ≥ median
%HRS + PCNA < median (= 52.72%) ≥ median
%HRS + p53 < median (= 53.45%) ≥ median
LP = lymphocyte predominance; NE = nodular sclerosis; MC = mixed cellularity; LD = lymphocyte depletion; WBC = whole 
blood count; ESR = erythrocyte sedimentation rate; HRS = Hodgkin and Reed-Sternberg cells; MDM2 = murine double minute-2 
antigen; PCNA = proliferating cell nuclear antigen;* bone marrow inﬁ ltration: positive: presence of bone marrow involvement 
of HD; negative: absence of bone marrow HD inﬁ ltration. 
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with a 100-dot integrator (Zeiss), in ﬁ ve 
randomly chosen different ﬁ elds. In every 
case, a positive-negative ratio was calculated 
for HRS and L after speciﬁ c and general 
proportion ratios for positive and negative 
L and HRS cells had been obtained.
Statistical analysis 
The tests used were the Wilcoxon 
test and Spearman coefﬁ cient to compare 
marker expression between HRS and L, 
Friedman’s test to determine differences 
between the markers (PCNA, p53 and 
MDM2) in HRS and L, and Pearson’s chi-
squared test to evaluate clinical and labora-
tory variables. CR achievement and OS were 
calculated by the Kaplan-Meier method and 
the curves were compared using log-rank 
tests. Multivariate analysis was based on 
the Cox regression model. Variables were 
dichotomized for univariate and multivari-
ate analysis regarding CR achievement and 
OS. Two-tailed p < 0.05 was considered 
statistically signiﬁ cant.
RESULTS
There was preponderance of male sub-
jects: 34 patients were male (67%) and 17 
were female (33%). Their ages ranged from 
9 to 88 years (median: 32 years). Nodular 
sclerosis was the most common histologi-
cal subtype and was found in 38 patients 
(74.5%), followed by mixed cellularity in 
seven patients (13.7%), lymphocyte de-
pletion in three (5.8%) and lymphocyte 
predominance in three (5.8%). Ann Arbor 
clinical stage I was found in three patients 
(5.8%), II in 14 (27.4%), III in 16 (31.3%) 
and IV in 18 (35.3%). Therefore, 66.6% 
had advanced disease (stage III or IV) at 
diagnosis. Moreover, 36 out of the 51 pa-
tients (72.5%) presented with B symptoms.
The ﬁ rst-line therapy was thus the MOPP/
ABV hybrid for 39 patients, MOPP for six 
patients and the MOPP/ABVD alternative 
scheme in four cases.24 Involved-ﬁ eld radiation 
therapy was performed in 28 cases and extend-
ed-ﬁ eld radiation therapy in 12 patients.
The median hemoglobin level was 
11.7 g/dl (ranging from 4.4 g/dl to 16.3 g/dl), 
median WBC was 8 x 109/µl, median ESR was 
58 mm/h and median alkaline phosphatase was 
233 U/l. Bone marrow analysis was negative in 
40 patients, positive in eight and not available 
in three patients.
The mean MDM2 expression was 60% 
in HRS and 20.7% in L (p < 0.001). For p53, 
the mean expression was 52.9% in HRS and 
5.9% in L (p < 0.001). For PCNA, the mean 
expression was 53.4% in HRS  and 20% in L 
(p < 0.001) (Graphs 1, 2 and 3 and Tables 1, 
2, 3 and 4). The expression of these tumor 
markers in HRS was predominantly in the 
nucleus, and was more positive in tumors than 
in reactive lymphocytes, for all three markers 
(Figures 1, 2 and 3 and Graphs 1, 2, 3 and 4). 
PCNA, p53 and MDM2 were not as-
sociated with gender, age, clinical stage, B 
symptoms, histological subtype, hemoglobin 
level, WBC, alkaline phosphatase, ESR or 
bone marrow involvement (Tables 2, 3 and 4). 
Univariate analysis between the proportions of 
marker expression in the tumor cells and all other 
variables investigated showed tendencies to cor-
relate between MDM2 and PCNA (p = 0.07) 
(Graph 5, Table 2); PCNA and p53 
(p = 0.12) (Graph 5 and Tables 3 and 4); 
alkaline phosphatase index higher than 150 
U and MDM2 (p = 0.09); and unfavorable 
histology and p53 (p = 0.15) (Tables 1, 2, 
3 and 4), but there was no association of 
marker expression between MDM2 and p53
(p = 0.88 in the Kaplan-Meier test) (Graph 5 and 
Tables 3 and 4). Multivariate statistical analysis 
also showed no signiﬁ cant differences. 
The expression of different markers had 
no signiﬁ cant inﬂ uence on CR achievement: 
p53 (p = 0.49); MDM2 (p = 0.59) and PCNA 
(p = 0.62). No signiﬁ cant inﬂ uence on OS was 
found in relation to PCNA (p = 0.13), MDM2 
(p = 0.21) or p53 (p = 0.54). The median OS 
for the study and control groups has not yet 
been reached. Therefore, we used the whole avai-
lable population of 93 patients to analyze any pos-
sible associations for ﬁ rst CR and OS in relation 
to the other variables. The univariate analysis for 
the likelihood of achieving the ﬁ rst CR showed 
that B symptoms (p < 0.001), WBC ≥ 10 x 109/µl
(p = 0.01), stage (III + IV) (p = 0.01) and hemo-
globin < 12 g/dl (p = 0.04) negatively inﬂ uenced 
the possibility of achieving this. The results for 
bone marrow inﬁ ltration (p = 0.07) and age 
(p = 0.17) were close to reaching signiﬁ cance. 
The Cox regression model indicated that B 
symptoms (p = 0.001) and WBC ≥ 10 x 109/µl
(p = 0.01) were independent from the other 
analyzed variables in relation to the ﬁ rst CR. 
All the patients without B symptoms 
(n = 22) and those with ESR less than 20 (n = 7) 
were still alive at the end of this study. However, 
these ﬁ ndings made it impossible to input these 
variables for multivariate analyses for OS.
In the univariate analysis, marrow in-
volvement (p = 0.05), hemoglobin < 12 g/dl 
(p = 0.06), WBC ≥ 10 x 109/µl (p = 0.07) and 
male sex (p = 0.1) showed tendencies towards 
lower OS. The log rank test demonstrated that 
bone marrow inﬁ ltration (p = 0.002), B symp-
toms (p = 0.03) and hemoglobin < 12 g/dl 
(p = 0.04) had a negative inﬂ uence on OS. 
With regard to the CR ratios, 33/45 (73.3%) 
in the study group and 36/48 (75%) among 
the controls achieved CR; 6/45 (13.3%) 
in the study group and 3/48 (6.2%) among the 
controls obtained partial response; and 6/45 
(13.3%) in the study group and 9/48 (18.7%) 
among the controls failed to achieve remission 
after the ﬁ rst treatment measures.
Figure 1. Photomicrograph of lymph 
node showing nuclear p53 expression 
in Reed-Sternberg cells, developed by 
peroxidase; 1000x magniﬁ cation.
Figure 2. Photomicrograph of lymph node 
showing nuclear MDM2 expression in Hodg-
kin cells (upper right and left arrows) and 
lymphocytes (lower right arrow), developed 
by peroxidase; 400x magniﬁ cation.
Figure 3. Photomicrograph showing nuclear 
PCNA expression in Reed-Sternberg cells 
and some Hodgkin cells (arrow), developed 
by peroxidase; 1000x magniﬁ cation. 
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DISCUSSION
HD is a unique human neoplasm consis-
ting of a benign component of lymphocytes, 
plasmacytes, eosinophils and neutrophils with 
evident cellular polymorphism, in association 
with a much smaller component of tumor 
cells (HRS) comprising around 1% of the 
tumor mass.1-3
The cell proliferation rate is an important 
parameter for better understanding of the 
clinical picture and for guiding the appropri-
ate therapy. PCNA monoclonal antibodies 
allow cell proliferation to be evaluated in 
clinical practice using immunohistochemical 
methods.10-12 In non-neoplastic small lym-
phocytes in HD tissues, PCNA expression 
is always low.10-12,26,27 Schmid et al.28 evalu-
ated 23 cases of HD by double labeling with 
PC-10 monoclonal antibody and CD20 (B 
cells), and PC-10 and CD45RO (T cells), and 
found positivity in 50.4% of HRS and 4.3% 
of lymphocytes. HRS cells express PCNA in 5 
to 100% of the cases. It has been demonstrated 
that the intensity of PCNA expression has an 
inﬂ uence over clinical stages and response to 
treatment.12,27,28
We found PCNA-positive rates for HRS 
cells that ranged from 36.9% to 73.68% 
(median of 52.7%), which were similar to 
previously reported studies.10-12 We found 
higher values for PCNA in reactive lym-
phocytes than did most previous researchers 
(median of 18.8%).12,27,28 These differences are 
probably due to variations in the methods and 
discrepancies in manual cell counts between 
the individuals doing the counting.
There are many studies evaluating p53 
and MDM2 expression in neoplasms. p53
mutations without differences in protein 
expression have been reported.15,17-19,21,22 We 
characterized p53 using two different clones: 
BP and DO7. p53 expression was similar for 
these two clones (data not shown). This indi-
cates that p53 expression in the wild type or 
in the mutated form may be evaluated using 
immunohistochemical methods either in fresh 
tissue or in formalin-ﬁ xed, parafﬁ n-embedded 
preserved material. The application of this 
analysis depends on the characteristics and 
speciﬁ city of the monoclonal or polyclonal 
antibodies for p53.15,16,20,26,29
Latent EBV infection was initially sug-
gested as a possible cause for p53 mutation.
This hypothesis has never been conﬁ rmed in 
clinical studies. The possibility of an associa-
tion between latent EBV infection and p53 
was ﬁ rst evaluated by Neidobitek et al.30 in 
37 patients in 1993. Only seven cases that 
were positive for p53 were also positive for 
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Graph 1. Dispersion of proportional values for MDM2 expression between Hodgkin 
and Reed-Sternberg (HRS) cells and lymphocytes (L).
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Graph 2. Dispersion of proportional values for p53 expression between Hodgkin and 
Reed-Sternberg (HRS) cells and lymphocytes (L). 
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Graph 3. Dispersion of proportional values for proliferating cell nuclear antigen (PCNA) 
expression between Hodgkin and Reed-Sternberg (HRS) cells and lymphocytes (L). 
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EBV proteins (EBER-1 or EBER-2). It is 
assumed that an association between p53 
and EBV could be a consequence of EBV 
encoding proteins that are bonded to p53. 
Chilosi et al.17 investigated nuclear EBV using 
in situ hybridization for EBER-1 and im-
munohistochemistry for LMP-1 after double 
staining for p53 and MDM2. They found that 
12 out of 72 patients who were positive for 
EBV were also positive for MDM2 and p53 
concomitantly.
The role of MDM2 protein expression 
in activating/inhibiting the p53 gene and in 
stabilizing p53 has also already been stud-
ied. Chen et al.20 showed that there was no 
relationship between MDM2 expression and 
p53 mutations. MDM2 and p53 expression 
in HRS cells ranged from 30 to 80%.12,17,21,26
In our study, concomitancy of p53 and MDM2 
was found in only 37% of the cases. The lowest 
marker expression in reactive lymphocytes that 
we found, especially for p53, was comparable 
to previous descriptions.12,16,17,21,26 Positive 
lymphocyte reactions for PCNA and MDM2 
at similar frequencies have also often been 
reported.10-12,17,18,26,31 Our positive results for 
PCNA, p53 and MDM2 in HRS cells are 
similar to those described by Martinez-Delgado 
et al.29 and Sánchez-Beato et al.26 In both of 
those studies, double staining for p53/MDM2 
was performed and variable marker expression 
in HRS cells was also found.
Using histomorphometric techniques 
taking median values as thresholds, we found 
that the numerical expression of MDM2 was 
higher than those of PCNA and p53 in HRS 
cells, while there was no difference between 
PCNA and p53 expressions. The possible ex-
planations for this ﬁ nding are: 1) the antigen 
recovery technique utilized may have led to 
higher expression of epitopes for MDM2-
speciﬁ c antibodies; 2) MDM2 protein stability 
may be higher in formalin-ﬁ xed, parafﬁ n-em-
bedded tissue; 3) the characteristics of the anti-
bodies utilized; and 4) the balance between the 
p53 and MDM2 pathways may favor MDM2 
expression because of other mechanisms 
for p53 inhibition. We found a statistically 
signiﬁ cant lower proportion of lymphocytes 
were positive for p53 than were positive for 
PCNA and MDM2. This was also observed 
by Smolewski et al. in 1998,31 who described 
mean reactivity of lymphocytes for PCNA of 
39.6%. According to most published studies, 
PCNA was expressed at higher frequencies 
than was p53.21,26,31 Histomorphometry was 
comparable to computed readings in the 
study by Sánchez-Beato et al.26 in 1996, for 
both markers.
Graph 4. Comparison of positive lymphocyte (L) expression for MDM2, p53 and 
proliferating cell nuclear antigen (PCNA).
Table 2. Univariate analysis. Odds ratios (OR) for the percentage of positivity in Hodgkin 
and Reed-Sternberg cells (%HRS+) (≥ mean or < mean) for PCNA
Variable N OR 95% CI p
%HRS+ for MDM2 51 0.35 0.113–1.095 0.071
%HRS+ for p53 51 2.40 0.780–7.389 0.127
Alkaline phosphatase 46 2.31 0.632–8.469 0.205
WBC 51 1.56 0.496–4.898 0.448
ESR 42 0.51 0.076–3.409 0.486
Histological subtype 51 1.58 0.386–6.423 0.526
Age 51 0.73 0.171–3.093 0.666
Clinical stage 51 1.27 0.394–4.063 0.692
Hemoglobin level 51 1.10 0.360–3.358 0.867
Gender 51 0.94 0.304–2.886 0.910
B symptoms 51 1.05 0.232–4.739 0.952
Bone marrow involvement 48 1.00 0.219–4.564 > 0.999
OR = odds ratio; CI = conﬁ dence interval; HRS = Hodgkin and Reed-Sternberg cells; PCNA = proliferating cell nuclear antigen, 
WBC = whole blood count; ESR = erythrocyte sedimentation rate.
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PCNA % L +P53 % L +MDM2 % L +
Friedman test: χ22gl = 59.65 (df = degrees of freedom); p < 0.001; dms = 23.67 (dms = minimum signiﬁ cant difference); MDM2 
versus p53: 123 - 57 = 66*; MDM2 versus PCNA: 123 - 126 = -3; p53 versus PCNA: 57 - 126 = -69*
Table 3. Univariate analysis. Odds ratios (OR) for the percentage of positivity in Hodgkin 
and Reed-Sternberg cells (%HRS+) (≥ mean or < mean) for MDM2
Variable n OR 95% CI p
%HRS+ for PCNA 51 0.35 0.113–1.095 0.071
Alkaline phosphatase 46 0.31 0.080–1.204 0.091
Clinical stage 51 1.81 0.556–5.886 0.324
B symptoms 51 0.57 0.121–2.702 0.481
Histological subtype 51 1.58 0.386–6.423 0.526
Age 51 0.73 0.171–3.093 0.666
Hemoglobin level 51 0.80 0.260–2.431 0.688
WBC 51 0.79 0.255–2.476 0.691
ESR 42 0.78 0.117–5.257 0.802
%HRS+ for p53 51 0.92 0.308–2.769 0.886
Bone marrow involvement 48 0.90 0.198–4.131 0.897
Gender 51 0.94 0.304–2.886 0.910
OR = odds ratio; HRS = Hodgkin and Reed-Sternberg cells; PCNA = proliferating cell nuclear antigen; CI = conﬁ dence interval; 
WBC = whole blood count; ESR = erythrocyte sedimentation rate.
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Our data show that, in the “benign” 
inﬂ ammatory component of HD, there are 
proliferating and differentiating lymphocytes 
that are morphologically normal but carry 
positivity for proliferation markers near to 
HRS cells. These lymphocytes may corre-
spond to precursors of HRS, as proposed by 
Hell et al.27 in 1993. The ﬁ nding of higher 
expression of MDM2 than of PCNA and 
p53 in HRS cells may raise the possibility of 
a feedback mechanism between the MDM2
and p53 genes.31-33
Table 4. Univariate analysis. Odds ratios (OR) for the percentage of positivity in Hodgkin 
and Reed-Sternberg cells (%HRS+) (≥ mean or < mean) for p53
Variable n OR 95% IC p
%HRS+ for PCNA 51 2.40 0.780–7.389 0.127
Histological subtypes 51 0.34 0.076–1.483 0.150
Age 51 0.41 0.091–1.876 0.252
Clinical stage 51 0.62 0.192–2.020 0.324
B symptoms 51 1.92 0.406–9.046 0.411
Bone marrow involvement 48 0.54 0.114–2.584 0.443
WBC 51 1.56 0.496–4.898 0.448
Hemoglobin level 51 1.52 0.496–4.685 0.462
ESR 42 1.42 0.212–9.518 0.717
Alkaline phosphatase 46 1.13 0.322–3.983 0.845
%HRS+ for MDM2 51 0.92 0.308–2.769 0.886
Gender 51 0.94 0.304–2.886 0.910
OR = odds ratio; HRS = Hodgkin and Reed-Sternberg cells; CI = conﬁ dence interval; PCNA = proliferating cell nuclear antigen; 
WBC = whole blood count; ESR = erythrocyte sedimentation rate; MDM2 = murine double minute-2 antigen.
Graph 5. Comparison of positive Hodgkin and Reed-Sternberg (HRS) cell expression 
for MDM2, p53 and proliferating cell nuclear antigen (PCNA). 
MDM2 % HRS + P53 % HRS + PCNA % HRS +
100
80
60
40
20
0
Friedman test: χ22df = 11.80 (df = degrees of freedom); p = 0.003; dms = 23.67 (dms = minimum signiﬁ cant difference); MDM2 
versus p53: 124 - 93 = 31*; MDM2 versus PCNA: 124 - 91 = 33*; p53 versus PCNA: 93 - 91 = 2
The occurrence of spontaneous apop-
tosis, as evaluated by the TUNEL (in situ 
nick-end labeling) technique, ranged from 
10 to 60% in HRS cells. The apoptosis 
index did not correlate with the histological 
and clinical findings, although a negative 
association with outcome was reported in 
110 cases by Smolewski et al.32 Its presence 
is not influenced by the EBV genome in 
HRS cells. PCNA, p53, p21 and caspase 3 
are associated with greater apoptosis indices, 
while BCL-2, MDM2, Rb-1 and P27 are 
not.32-35 In a smaller group of patients, it was 
conﬁ rmed that strong expression of PCNA, 
p53 and BCL-2 is associated with shorter OS 
and worse response to treatment.31,33 Brink et 
al.35 showed that the BCL-2+/p53– immu-
nophenotype presented the worst prognosis, 
while the BCL-2–/p53– immunophenotype 
had ﬁ ve-year OS of more than 90% and the 
p53+/BCL-2+ immunophenotype had the 
best prognosis.35 High expressions of LMP1-
EBV in HRS cells presented better response to 
therapy and better OS, while Rb-1 had worse 
prognosis. p53, BCL-2 and CD15 did not 
inﬂ uence the outcome.30,36-38 We emphasize 
that MDM2 and PCNA, MDM2 and p53 
expression, and also p53 expression versus 
unfavorable histology were close to reaching 
signiﬁ cance in the univariate analyses. These 
data show that, if a larger sample were used, a 
signiﬁ cant result might be found, as observed 
by other authors.17-19,33-35,39
B symptoms and WBC counts higher 
than 10x109/µl were unfavorable independ-
ent factors for achieving the first CR. Bone 
marrow tumor infiltration, B symptoms 
and hemoglobin levels less than 12 g/dl had 
a negative influence on OS. These data have 
also been reported as negative prognostic 
factors for survival in HD.24,32,34,39 The 
present study was a retrospective analysis, 
but these findings have led us to attempt 
to be more specific regarding prognostic 
factors in this disease.38 The treatment for 
HD changed over the admission period 
for these patients, but the ratios of first 
CR and OS remained almost the same, 
because of the high sensitivity of the tumor 
to chemotherapy.34
CONCLUSIONS
The methods we have used showed that 
p53, PCNA and MDM2 are expressed in 
HRS cells at different intensities. Further 
studies with larger series are needed to 
elucidate the inﬂ uence of Epstein-Barr vi-
rus infection, frequency of Rb-1 gene loss 
and high expression of P21 on the clinical 
setting and the relationship of these three 
factors to treatment response in HD pa-
tients. The ﬁ nding of no clear association 
between the antigen expression evaluated 
and the clinical data may be explained by 
the limited number of patients, the retro-
spective nature of the study and the high 
expression of these proteins, which made 
stratiﬁ cation and the result interpretation 
methods used more difﬁ cult.
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RESUMO
Proliferação de antígeno de célula nuclear (PCNA), p53 e expressão de MDM2 em doença do Hodgkin
CONTEXTO E OBJETIVO: As células tumorais da doença de Hodgkin (HD) são positivas para marcadores 
de proliferação celular que são analisados por seus genes e respectivas proteínas. A correlação entre a 
expressão destas proteínas e os parâmetros clínico-laboratoriais são, no momento, de importância para 
o prognóstico da doença.
TIPO DE ESTUDO E LOCAL: Estudo retrospectivo da expressão do antígeno de proliferação celular (PCNA) 
e da p53 e MDM2 em tecidos obtidos ao diagnóstico, ﬁ xados por formol, embebidos em paraﬁ na de 
51 pacientes com HD. O trabalho foi realizado na Divisão de Hematologia e Transfusão, Hospital São 
Paulo, Universidade Federal de São Paulo.
MÉTODOS: As expressões antigênicas foram analisadas através da proporção de células de Hodgkin e 
células de Reed Sternberg (HRS) e linfócitos reacionais (L) positivos. A intensidade de expressão de cada 
proteína foi comparada entre L e HRS através do coeﬁ ciente de Spearman. A comparação da PCNA, p53 
e MDM2 em L e HRS se fez pelo teste de Fiedman. As correlações entre variáveis clínico-laboratoriais, 
comprometimento da medula óssea, taxas de sobrevida geral e remissão clínica com as proteínas em HRS 
se ﬁ zeram pelo coeﬁ ciente de Pearson.
RESULTADOS: Houve superexpressão das três proteínas em células HRS comparadas aos L (p < 0,001). 
Nas células HRS, a MDM2 foi maior que a p53 e a PCNA (p < 0,003), que foram equivalentes. Nos L, 
a p53 foi menor que a MDM2 e a PCNA (p < 0,001), que foram equivalentes Não houve relação entre 
as expressões das proteínas com as variáveis clínico-laboratoriais e sobrevida.
CONCLUSÕES: PCNA, p53 e MDM2 são marcadores tumorais na HD, porém não mostraram signiﬁ cado 
clínico-prognóstico em nossa análise.
PALAVRAS-CHAVE: Antígeno nuclear de célula em proliferação. Genes p53. Proteínas proto-oncogênicas 
c-mdm2. Doença de Hodgkin. Imunohistoquímica.
